0001209191-17-047197.txt : 20170802 0001209191-17-047197.hdr.sgml : 20170802 20170802182735 ACCESSION NUMBER: 0001209191-17-047197 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170731 FILED AS OF DATE: 20170802 DATE AS OF CHANGE: 20170802 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KINGSLEY ALFRED D CENTRAL INDEX KEY: 0001229339 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12830 FILM NUMBER: 171001599 MAIL ADDRESS: STREET 1: 150 E 57TH STREET CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOTIME INC CENTRAL INDEX KEY: 0000876343 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943127919 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1010 ATLANTIC AVENUE STREET 2: SUITE 102 CITY: ALAMEDA STATE: CA ZIP: 94501 BUSINESS PHONE: 5105213390 MAIL ADDRESS: STREET 1: 1010 ATLANTIC AVENUE STREET 2: SUITE 102 CITY: ALAMEDA STATE: CA ZIP: 94501 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-07-31 0 0000876343 BIOTIME INC BTX 0001229339 KINGSLEY ALFRED D 150 E. 57TH STREET NEW YORK NY 10022 1 1 0 0 See Remarks Common Shares, no par value 2017-07-31 4 S 0 150000 2.80 D 5781555 D Common Shares, no par value 1143346 I By Greenbelt Corp. Common Shares, no par value 375351 I By Greenway Partners, LP Option to Purchase Common Shares 3.15 2022-06-30 Common Shares 50000 50000 D Option to Purchase Common Shares 2.72 2021-06-30 Common Shares 50000 50000 D Option to Purchase Common Shares 3.57 2020-06-30 Common Shares 50000 50000 D Option to Purchase Common Shares 3.11 2019-06-30 Common Shares 50000 50000 D Option to Purchase Common Shares 4.13 2018-06-30 Common Shares 50000 50000 D The securities were sold in a private transaction. Substantially all of the sale proceeds were invested in AgeX Therapeutics, Inc., a new subsidiary of BioTime. Does not include shares that Mr. Kingsley may acquire through the exercise of certain options. Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2017 based upon continued service on the board of directors. Became exercisable in four equal quarterly installments after the date of grant on July 1, 2016. Became exercisable in four equal quarterly installments after the date of grant on July 1, 2015. Became exercisable in four equal quarterly installments after the date of grant on July 1, 2014. Became exercisable in four equal quarterly installments after the date of grant on July 1, 2013. Mr. Kingsley is Chairman of certain BioTime subsidiaries. /s/Alfred D. Kingsley 2017-08-02